Synopsis: Orchid Pharma Ltd. shares jumped 13% following the announcement of its licensing and supply agreement with Pharmasyntez JSC, Russia, for the commercialization of Exblifep®. The deal is expected to strengthen the company’s global presence and unlock a significant market opportunity in the anti-infective segment.
The shares of the small-cap company, which specializes in the discovery, development, and global manufacturing of cephalosporin antibiotics, are in focus following the signing of a licensing and supply agreement in Russia.
With a market capitalization of Rs. 5,137.85 crores in the day’s trade, the shares of Orchid Pharma Ltd jumped upto 13 percent, making a high of Rs. 1,047.50 per share compared to its previous closing price of Rs. 926.65 per share.
What Happened
Orchid Pharma Ltd. has entered into a licensing and supply agreement with Pharmasyntez JSC, Russia, for the commercialization of Exblifep® (Cefepime/Enmetazobactam) in the Russian market, subject to regulatory approval from the Ministry of Health of the Russian Federation.
Exblifep® is a novel combination antibiotic developed for treating complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative bacterial pathogens.
The product is a carbapenem-sparing antibiotic designed to address infections caused by ESBL-producing Gram-negative bacteria. It has received approval from the U.S. FDA and the European Medicines Agency (EMA) and is included in IDSA and EUCAST treatment guidelines.
Under the agreement, Pharmasyntez will have exclusive rights to register and commercialize Exblifep® in Russia, while Orchid Pharma will supply the finished dosage form. The partnership represents a significant market opportunity, estimated at approximately USD 178 million over the first 10 years, driven by the growing clinical need and hospital procurement demand in Russia.
Management Commentary
Manish Dhanuka, Managing Director, Orchid Pharma Ltd.-“Our partnership with Pharmasyntez marks an important step in making Exblifep available to patients in Russia. Pharmasyntez’s deep reach into the Russian hospital procurement system makes them the right partner to ensure this medicine gets to the clinicians and patients who need it.”
Natalia Malykh, Vice President of Business Development at the Pharmasyntez group, said, “Antimicrobial resistance is one of the most significant challenges facing modern medicine, making the development of new antibiotics critical. Orchid Pharma has met this challenge by developing the novel antibiotic Exblifep® (cefepime/enmetazobactam). This licensing agreement with Pharmasyntez enables Russian patients to gain access to modern antibacterial therapy.”
Can Russia Deal Fuel Orchid Pharma’s Next Growth Phase?
Orchid Pharma’s licensing and supply agreement with Pharmasyntez JSC for Exblifep® commercialization in Russia could become a meaningful growth catalyst for the company. The deal provides Orchid Pharma access to the Russian market through an exclusive commercialization partner, while allowing the company to generate revenue by supplying the finished dosage form.
With the market opportunity estimated at around USD 178 million over the first 10 years, the agreement creates a potential long-term revenue stream beyond Orchid Pharma’s existing operations. The growth opportunity is supported by rising demand for advanced antibiotics targeting difficult-to-treat Gram-negative bacterial infections, particularly ESBL-producing pathogens.
Exblifep®, already approved by the U.S. FDA and European Medicines Agency and recognized in international treatment guidelines, strengthens Orchid Pharma’s global positioning in the anti-infective segment. If regulatory approval is secured in Russia and adoption increases through hospital procurement, the partnership could contribute to Orchid Pharma’s next phase of international expansion and revenue growth.
Financials & Others
The company’s revenue rose by 0.05 percent from Rs. 237 crores in Q4FY2025 to Rs. 238 crores in Q4FY2026. Net profit rose from Rs. 22 crores to Rs. 24 crores during the same period.
Orchid Pharma Limited is a fully vertically integrated pharmaceutical company with end-to-end capabilities across Key Starting Materials (KSMs), Active Pharmaceutical Ingredients (APIs), and Finished Dosage Forms (FDFs), with a focus on complex injectable antibiotics.
The company is the first Indian pharmaceutical company to develop a New Chemical Entity (NCE) approved in both the United States and Europe. Its products are commercially marketed in Europe and India, supported by globally approved manufacturing facilities compliant with USFDA and EU-GMP standards.
Global Antibiotics Market Overview
The global antibiotics market was valued at approximately $45 billion in 2025 and is projected to grow at a 2.5% CAGR through 2035, reaching around $57 billion by 2034. The market growth is driven by increasing demand for antibiotic therapies, rising infectious disease burden, and advancements in drug development.
In 2026, Cephalosporins (32%) and Penicillins (28%) represent the largest shares of the global antibiotic drug market, followed by Others (18%), Macrolides (8%), Carbapenems (8%), and Fluoroquinolones (6%). The Cephalosporin market was valued at around $15 billion in 2025, with approximately 15–20% attributed to API production and 80% to finished dosage formulations.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
